Published in Drug Week, September 10th, 2004
AMG 162 is an investigational, fully human monoclonal antibody that specifically binds to and inhibits RANK Ligand, the primary mediator of bone resorption. Amgen scientists have confirmed that RANK Ligand is the protein responsible for activating osteoclasts, the cells that break down bone.
Excessive RANK Ligand has been identified as the primary cause of a broad range of bone loss conditions...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.